Genmab and Synaffix have signed a license agreement providing Genmab broad access to Synaffix’s ADC technologies. The company is granted exclusive research rights to utilise Synaffix ADC technologies for one drug target with the option for the worldwide development and commercialisation of the resulting ADCs. It also has the option to exercise exclusive research and commercial licenses for additional targets.
For each specific target nominated under the license agreement, the company gains exclusive access to Synaffix’s clinical-stage GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, as well as select toxSYN linker-payloads. Each technology is designed to help enable ADCs with high efficacy and tolerability for multiple potential therapies.
Genmab will be responsible for the research, development, manufacturing and commercialisation of any resulting ADC therapies. At the same time, Synaffix will support the research activities, including manufacturing of components specifically related to its proprietary ADC technologies.
“At Genmab, we are committed to bringing differentiated medicines to patients, and we believe collaborations are foundational to accelerate innovation,” said Jan van de Winkel, CEO, Genmab. “We look forward to working with Synaffix toward our shared goal of developing best-in-class or first-in-class antibody therapies and make an impact on the lives of patients.”
“In what represents our fifth out-licensing deal in the last six months, we are thrilled to partner with Genmab, an international biotechnology company,” said Peter van de Sande, CEO of Synaffix. “In deploying our cutting-edge ADC technology platform together with Genmab’s robust antibody development capabilities, Synaffix is privileged to once more play an essential role in strengthening a partner’s pipeline with our innovative ADC technologies thereby aiding the transformation of cancer treatment.”
